Table 2.

OS according to confirmed biomarkers

Univariate survival analysis
FactorTotal nCategoriesn (%)% DeadMedian survival (months)1-Year survival rate (95% CI)2-Year survival rate (95% CI)3-Year survival rate (95% CI)P
LDH-ratio205≤1.2139 (67.8)69.11048.3(39.9–56.7)27.0(18.8–35.2)22.6(14.4–30.8)1.54E−12
>1.244 (21.5)88.6518.2(6.2–30.2)10.9(0.3–21.5)7.3(0.0–16.5)
>2.322 (10.7)100.024.5(0.0–13.1)
RLC204<10.5%20 (9.8)100.025.0(0.0–14.6)3.30E−12
≥10.5%184 (90.2)72.8840.8(33.6–48.1)24.3(17.4–31.3)20.1(13.2–27.0)
AMC204<650/μL165 (80.9)70.9942.6(34.9–50.4)26.1(18.6–33.5)22.3(14.8–29.9)1.35E−08
≥650/μL39 (19.1)94.9215.4(4.1–26.7)3.8(0.0–11.0)
AEC204<50/μL54 (26.5)88.9421.6(10.5–32.7)6.7(0.0–14.8)5.06E−05
≥50/μL150 (73.5)70.7942.9(34.8–51.1)27.2(19.3–35.1)22.2(14.3–30.1)
REC204<1.5%89 (43.6)85.4624.8(15.5–34.1)12.1(4.2–20.0)7.5(0.5–14.6)2.14E−04
≥1.5%115 (56.4)67.8946.8(37.5–56.1)29.2(20.0–38.4)25.9(16.7–35.2)
CD4+CD25+FoxP3+ Tregs155<1.5%14 (9.0)100.037.1(0.0–20.6)8.70E−05
≥1.5%141 (91.0)72.3943.3(34.9–51.7)23.8(15.9–31.8)21.2(13.4–29.1)
CD14+ Monocytes189<28%162 (85.7)70.4943.5(35.7–51.4)26.4(18.8–34.0)22.9(15.3–30.5)6.58E−07
≥28%27 (14.3)96.3413.3(0.0–26.7)
LinCD14+HLA-DR−/low MDSCs164<5.1%99 (60.4)64.61351.2(41.1–61.3)34.5(24.2–44.9)29.4(19.0–39.8)6.73E−11
≥5.1%39 (23.8)87.2524.9(11.1–38.6)
≥9.5%26 (15.9)92.3315.4(1.5–29.3)
  • Abbreviations: AEC, absolute eosinophil counts; AMC, absolute monocyte counts; HR, hazard ratio; LDH, lactate dehydrogenase; MDSCs, myeloid-derived suppressor cells; REC, relative eosinophil counts; RLC, relative lymphocyte counts; Tregs, regulatory T cells.